Skip to main content
. 2012 Jan;56(1):341–351. doi: 10.1128/AAC.05537-11

Fig 4.

Fig 4

Synergistic effect of combinations of F18 with ARVs in inhibition of drug-resistant HIV-1 infection in PBMCs. The concentration ratio between F18 and other ARVs was 3:1. (A) F18 plus NVP against NVP-resistant virus; (B) F18 plus AZT against AZT-resistant virus; (C) F18 plus NVP against 3TC-resistant virus; (D) F18 plus NVP against PI-resistant virus; (E) F18 plus d4T against multiresistant virus. M refers to drug combinations.